News 2014

Cancer Active Immunotherapy OBI-822 Mechanelism Action

Introduction of OBI PHARMA, INC.’s

OBI Pharma Announces Completion of Patient Enrollment in Phase 2/Phase 3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer

TAIPEI, TAIWAN, July 22/ — OBI Pharma, Inc., a Taiwan biotech company (GreTai 4174:TT), announced that it has completed patient enrollment in its Phase 2/3 clinical trial evaluating the safety …

OBI Pharma, Inc. won Taiwan “Venture Capital Star” The Best Investment Award

The Republic of China Venture Capital Association hosted its “Venture Capital Star” event and award night on January 15, 2014, and OBI Pharma, Inc. was selected and given the “Best …